HOUSTON - Kiromic BioPharma, Inc. (OTCQB: KRBP) has reported preliminary results from its Deltacel-01 Phase 1 clinical trial indicating tumor stabilization in a patient with stage 4 metastatic non-small cell lung cancer (NSCLC). The patient, treated at Beverly Hills Cancer Center, showed no new metastatic disease sites and maintained disease stability at existing sites, according to imaging conducted six weeks post-treatment.
The trial's Safety Monitoring Committee (SMC) has recommended maintaining the initial cell dose level for the next patient cohort after reviewing safety and efficacy data from the first three patients. This decision was influenced by the observed safety, tolerability, and signs of anti-tumor activity of Deltacel™ (KB-GDT-01), Kiromic's allogeneic Gamma Delta T-cell (GDT) therapy.
The Deltacel-01 trial, which includes patients who have not responded to standard therapies, involves two intravenous infusions of Deltacel™ combined with low-dose radiation. The primary aim is to assess safety, while secondary objectives include various measures of treatment efficacy.
Deltacel™ is designed to harness the natural cancer-targeting properties of GDT cells and is currently the lead candidate in Kiromic's GDT platform. Preclinical studies have supported its safety and efficacy, particularly when paired with radiation.
Kiromic BioPharma is a clinical-stage company focusing on developing cell therapies for immuno-oncology, utilizing its proprietary DIAMOND® artificial intelligence engine for target discovery.
The information in this article is based on a press release statement from Kiromic BioPharma. The company cautions that the statements within the press release are forward-looking and subject to substantial risks and uncertainties.
InvestingPro Insights
Kiromic BioPharma, Inc. (KRBP) has recently shown promising signs in its clinical trials, but a look at the company's financial health through InvestingPro data reveals a challenging landscape. With a market cap of just 3.86 million USD, the company operates with a significant debt burden and is quickly burning through cash. This is reflected in their adjusted operating income for the last twelve months as of Q4 2023, which stands at a loss of 19.94 million USD.
InvestingPro data also shows a price to earnings (P/E) ratio of -0.17, suggesting that investors are wary of the company's earnings potential. Additionally, the company's stock price has experienced high volatility, with a 224.32% return over the last three months and an impressive 934.48% return over the last six months, indicating potential investor optimism or speculative trading.
InvestingPro Tips for Kiromic BioPharma highlight several areas of concern, including weak gross profit margins and expectations that net income will drop this year. The company's short-term obligations also exceed its liquid assets, which could pose liquidity risks. On a more positive note, despite not paying a dividend, the stock has seen a strong return over the last month.
For readers interested in a deeper dive into Kiromic BioPharma's financials and future prospects, there are an additional 14 InvestingPro Tips available at https://www.investing.com/pro/KRBP. These tips could provide valuable insights for investors looking to make informed decisions. Remember to use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, offering even more expert analysis and data for your investment strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.